514 related articles for article (PubMed ID: 27115515)
21. PAR-2 inhibition reverses experimental pulmonary hypertension.
Kwapiszewska G; Markart P; Dahal BK; Kojonazarov B; Marsh LM; Schermuly RT; Taube C; Meinhardt A; Ghofrani HA; Steinhoff M; Seeger W; Preissner KT; Olschewski A; Weissmann N; Wygrecka M
Circ Res; 2012 Apr; 110(9):1179-91. PubMed ID: 22461388
[TBL] [Abstract][Full Text] [Related]
22. EP3 receptor deficiency attenuates pulmonary hypertension through suppression of Rho/TGF-β1 signaling.
Lu A; Zuo C; He Y; Chen G; Piao L; Zhang J; Xiao B; Shen Y; Tang J; Kong D; Alberti S; Chen D; Zuo S; Zhang Q; Yan S; Fei X; Yuan F; Zhou B; Duan S; Yu Y; Lazarus M; Su Y; Breyer RM; Funk CD; Yu Y
J Clin Invest; 2015 Mar; 125(3):1228-42. PubMed ID: 25664856
[TBL] [Abstract][Full Text] [Related]
23. Loss of SMAD3 Promotes Vascular Remodeling in Pulmonary Arterial Hypertension via MRTF Disinhibition.
Zabini D; Granton E; Hu Y; Miranda MZ; Weichelt U; Breuils Bonnet S; Bonnet S; Morrell NW; Connelly KA; Provencher S; Ghanim B; Klepetko W; Olschewski A; Kapus A; Kuebler WM
Am J Respir Crit Care Med; 2018 Jan; 197(2):244-260. PubMed ID: 29095649
[TBL] [Abstract][Full Text] [Related]
24. Disruption of TGF-β signaling in smooth muscle cell prevents flow-induced vascular remodeling.
Gao F; Chambon P; Tellides G; Kong W; Zhang X; Li W
Biochem Biophys Res Commun; 2014 Nov; 454(1):245-50. PubMed ID: 25451249
[TBL] [Abstract][Full Text] [Related]
25. Fluorofenidone attenuates vascular remodeling in hypoxia-induced pulmonary hypertension of rats.
Li XW; Du J; Hu GY; Hu CP; Li D; Li YJ; Li XH
Can J Physiol Pharmacol; 2014 Jan; 92(1):58-69. PubMed ID: 24383874
[TBL] [Abstract][Full Text] [Related]
26. Reversal effects of low-dose imatinib compared with sunitinib on monocrotaline-induced pulmonary and right ventricular remodeling in rats.
Leong ZP; Okida A; Higuchi M; Yamano Y; Hikasa Y
Vascul Pharmacol; 2018 Jan; 100():41-50. PubMed ID: 29100963
[TBL] [Abstract][Full Text] [Related]
27. Expression of TGF-beta1 and its receptor genes (TbetaR I, TbetaR II, and TbetaR III-betaglycan) in peripheral blood leucocytes in patients with idiopathic pulmonary arterial hypertension and Eisenmenger's syndrome.
Jachec W; Foremny A; Domal-Kwiatkowska D; Smolik S; Tomasik A; Mazurek U; Wodniecki J
Int J Mol Med; 2008 Jan; 21(1):99-107. PubMed ID: 18097622
[TBL] [Abstract][Full Text] [Related]
28. Chimeric extracellular domain type II transforming growth factor (TGF)-beta receptor fused to the Fc region of human immunoglobulin as a TGF-beta antagonist.
Komesli S; Vivien D; Dutartre P
Eur J Biochem; 1998 Jun; 254(3):505-13. PubMed ID: 9688260
[TBL] [Abstract][Full Text] [Related]
29. Valsartan attenuates pulmonary hypertension via suppression of mitogen activated protein kinase signaling and matrix metalloproteinase expression in rodents.
Lu Y; Guo H; Sun Y; Pan X; Dong J; Gao D; Chen W; Xu Y; Xu D
Mol Med Rep; 2017 Aug; 16(2):1360-1368. PubMed ID: 28586065
[TBL] [Abstract][Full Text] [Related]
30. Alterations in TGF-beta1 expression in lambs with increased pulmonary blood flow and pulmonary hypertension.
Mata-Greenwood E; Meyrick B; Steinhorn RH; Fineman JR; Black SM
Am J Physiol Lung Cell Mol Physiol; 2003 Jul; 285(1):L209-21. PubMed ID: 12665463
[TBL] [Abstract][Full Text] [Related]
31. Assignment of transforming growth factor beta1 and beta3 and a third new ligand to the type I receptor ALK-1.
Lux A; Attisano L; Marchuk DA
J Biol Chem; 1999 Apr; 274(15):9984-92. PubMed ID: 10187774
[TBL] [Abstract][Full Text] [Related]
32. Targeting all transforming growth factor-β isoforms with an Fc chimeric receptor impairs tumor growth and angiogenesis of oral squamous cell cancer.
Takahashi K; Akatsu Y; Podyma-Inoue KA; Matsumoto T; Takahashi H; Yoshimatsu Y; Koinuma D; Shirouzu M; Miyazono K; Watabe T
J Biol Chem; 2020 Sep; 295(36):12559-12572. PubMed ID: 32631954
[TBL] [Abstract][Full Text] [Related]
33. Calpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of disease.
Ma W; Han W; Greer PA; Tuder RM; Toque HA; Wang KK; Caldwell RW; Su Y
J Clin Invest; 2011 Nov; 121(11):4548-66. PubMed ID: 22005303
[TBL] [Abstract][Full Text] [Related]
34. Macrophage-Derived Legumain Promotes Pulmonary Hypertension by Activating the MMP (Matrix Metalloproteinase)-2/TGF (Transforming Growth Factor)-β1 Signaling.
Bai P; Lyu L; Yu T; Zuo C; Fu J; He Y; Wan Q; Wan N; Jia D; Lyu A
Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):e130-e145. PubMed ID: 30676070
[TBL] [Abstract][Full Text] [Related]
35. Inhibitory effects of tranilast on expression of transforming growth factor-beta isoforms and receptors in injured arteries.
Ward MR; Sasahara T; Agrotis A; Dilley RJ; Jennings GL; Bobik A
Atherosclerosis; 1998 Apr; 137(2):267-75. PubMed ID: 9622270
[TBL] [Abstract][Full Text] [Related]
36. In the absence of type III receptor, the transforming growth factor (TGF)-beta type II-B receptor requires the type I receptor to bind TGF-beta2.
del Re E; Babitt JL; Pirani A; Schneyer AL; Lin HY
J Biol Chem; 2004 May; 279(21):22765-72. PubMed ID: 14996829
[TBL] [Abstract][Full Text] [Related]
37. The transforming growth factor-beta/Smad2,3 signalling axis is impaired in experimental pulmonary hypertension.
Zakrzewicz A; Kouri FM; Nejman B; Kwapiszewska G; Hecker M; Sandu R; Dony E; Seeger W; Schermuly RT; Eickelberg O; Morty RE
Eur Respir J; 2007 Jun; 29(6):1094-104. PubMed ID: 17392319
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of FGFR Signaling With PD173074 Ameliorates Monocrotaline-induced Pulmonary Arterial Hypertension and Rescues BMPR-II Expression.
Zheng Y; Ma H; Hu E; Huang Z; Cheng X; Xiong C
J Cardiovasc Pharmacol; 2015 Nov; 66(5):504-14. PubMed ID: 26535780
[TBL] [Abstract][Full Text] [Related]
39. The key role of transforming growth factor-beta receptor I and 15-lipoxygenase in hypoxia-induced proliferation of pulmonary artery smooth muscle cells.
Liu Y; Ma C; Zhang Q; Yu L; Ma J; Zhang L; Hao X; Cao F; Wang L; Zhu D
Int J Biochem Cell Biol; 2012 Jul; 44(7):1184-202. PubMed ID: 22542888
[TBL] [Abstract][Full Text] [Related]
40. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling.
Klein M; Schermuly RT; Ellinghaus P; Milting H; Riedl B; Nikolova S; Pullamsetti SS; Weissmann N; Dony E; Savai R; Ghofrani HA; Grimminger F; Busch AE; Schäfer S
Circulation; 2008 Nov; 118(20):2081-90. PubMed ID: 18955668
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
